In preclinical studies of AML models, surface expression of FLT3 was increased specifically in FLT3–internal tandem duplication–positive AML cells after treatment with the FLT3 inhibitor crenolanib and was recognized by FLT3 CAR-T cells [120]. Here, FLT3 is linked to acute myeloid leukemia.